Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 12:56 AM
Ignite Modification Date:
2025-12-25 @ 12:56 AM
NCT ID:
NCT01867593
Eligibility Criteria:
Inclusion Criteria:
* Histologically or cytologically confirmed newly-diagnosed glioblastoma or gliosarcoma and planning to undergo standard chemoradiation treatment
* Life expectancy of at least 12 weeks
Exclusion Criteria:
* Pregnant or breastfeeding
* Glioblastoma involving the brainstem or posterior fossa, cerebrospinal fluid dissemination
* Chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas)
* Not recovered from adverse events due to previous treatment
* Have received any treatment regimen including a VEGF-R inhibitor such as bevacizumab or cediranib or plant to receive such agents
* Prior history of radiation therapy that would lead to overlap wtih new radiation fields
* Prior use of radiosensitizers, Gliadel wafers or other interstitial intracranial treatments
* Receiving any other study agent
* History of allergic reactions attributed to compounds of similar chemical or biologic composition to L-\[methyl\]-C methionine
* Prior invasive malignancy (except non-melanomatous skin cancer or disease free for at least 3 years)
* Inability to undergo MRI with gadolinium contrast or PET imaging
* Uncontrolled intercurrent illness
* HIV positive on antiretroviral therapy
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT01867593
Study Brief:
Protocol Section:
NCT01867593